Journal article
Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma
Abstract
INTRODUCTION: Proton pump inhibitors (PPIs) are potent inhibitors of gastric acid secretion and can affect the optimal absorption of concomitant oral medications, such as vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). The purpose of this study was to investigate the effect of PPI use on survival in metastatic renal cell carcinoma (mRCC) patients treated in the targeted therapy era.
MATERIALS AND METHODS: We …
Authors
Lalani A-KA; McKay RR; Lin X; Simantov R; Kaymakcalan MD; Choueiri TK
Journal
Clinical Genitourinary Cancer, Vol. 15, No. 6, pp. 724–732
Publisher
Elsevier
Publication Date
December 2017
DOI
10.1016/j.clgc.2017.05.019
ISSN
1558-7673
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAxitinibCarcinoma, Renal CellClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicDrug InteractionsFemaleGastrointestinal DiseasesHumansImidazolesIndazolesIndolesKidney NeoplasmsMaleMiddle AgedMolecular Targeted TherapyNiacinamidePhenylurea CompoundsProtein Kinase InhibitorsProton Pump InhibitorsPyrrolesSorafenibSunitinibSurvival AnalysisTreatment Outcome